Promoted Content Promoted Content

X

Market Place

Market Place

Menu

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Prices
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Novel Drugs for Hepatology (Liver, Pancreatic, Gall Bladder) under Development

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    Country filter
      News Type filter
        Company filter
          Product Type filter
            Deal Size filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Ionis Pharmaceuticals

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED STATES United States

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Virtual Innovation Day

              Participation Not Confirmed

              Update your events

              Ionis Announces third Investigational Antisense Medicine to treat Nonalcoholic Steatohepatitis (NASH) Enters Development

              Contact the Supplier

              Lead Product(s): ION455

              Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: ION455

              Highest Development Status: Undisclosed Product Type: Large molecule

              Partner/Sponsor/Collaborator: AstraZeneca PLC

              Deal Size: $330.0 million Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement November 23, 2020

              Details:

              AstraZeneca has licensed ION455, an investigational antisense medicine being developed as a potential treatment for nonalcoholic steatohepatitis (NASH).

              Axcella Health

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED STATES United States

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Virtual Innovation Day

              Participation Not Confirmed

              Update your events

              New Publication Highlights Therapeutic Potential of Endogenous Metabolic Modulators (EMMs)

              Contact the Supplier

              Lead Product(s): AXA1125

              Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: AXA1125